Ariana Pharma adds to clinical and safety services

Ariana Pharma, a French supplier of data management tools to accelerate drug discovery and development, has upgraded its Knowledge Extraction and Management (KEM) software with KEM Clinicals. The company is offering this as a service to pharmaceutical and biotechnology companies.

KEM Clinicals is not only capable of testing hypotheses (as other methods do) but will also generate robust hypotheses consistent with existing data relevant to the objectives sought. The company says this eliminates the bias stemming from poor initial information, a recurrent difficulty when using traditional statistical methods.

The software uses combinations of the following features: improved protocol design (optimal inclusion/exclusion criteria); early adverse events detection and characterisation; identification of surrogate endpoints; design of composite efficacy/safety endpoints; optimising benefit/risk ratio through analysis and characterising populations at the baseline.

In addition, KEM Clinicals will enable existing Ariana customers to shorten significantly the time taken to analyse clinical trial data by up to six weeks - typically from 10-14 weeks to 8-10 weeks.

'These major new enhancements show that Ariana has delivered on its commitment to expand further the capabilities of KEM, and allow the company to enter a new growth area, that of efficient clinical trial data analysis,' said Mohammad Afshar, ceo of Ariana Pharma.

'The earlier version of KEM already offered highly innovative techniques for clinical trials but KEM Clinicals will have a significant impact on efficacy and in producing reliable and exhaustive results fast,' he added.